Form 4: Director Charles Homcy Receives Maze Therapeutics Options

Director Charles J. Homcy was granted 18,000 stock options in Maze Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Charles J. Homcy received a grant of 18,000 stock options to purchase common stock in Maze Therapeutics, Inc.
• The options have an exercise price of $23.58 per share.
• The grant date for the transaction was June 8, 2026.
• The options are scheduled to expire on June 7, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer through the vesting date.

Future Outlook

The options vest on the earlier of the 2027 annual stockholders meeting or June 8, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board retention and alignment with company performance milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on or before June 8, 2027.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Director Compensation